GLP-1 & MetabolicFDA ApprovedS

Semaglutide

Ozempic / Wegovy / Rybelsus

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral daily, 2019). STEP 1 clinical trial demonstrated 14.9% average body weight reduction at 68 weeks with 2.4mg weekly. SELECT cardiovascular outcomes trial (2023) showed 20% reduction in major cardiovascular events.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
6
Research grade
S
Community score
63

Trend index

Trackers
376

Overview

About Semaglutide

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral daily, 2019). STEP 1 clinical trial demonstrated 14.9% average body weight reduction at 68 weeks with 2.4mg weekly. SELECT cardiovascular outcomes trial (2023) showed 20% reduction in major cardiovascular events.

Category
GLP-1 & Metabolic
Regulatory status
FDA Approved
Also known as
Ozempic / Wegovy / Rybelsus
Self-reports
26

Community

What 26 users report

26 community reports

Positive 4% · Neutral 96% · Negative 0%

Most reported benefits

Appetite
122

Most reported side effects

Nausea
117

Dose distribution

Median: 1000–2000 mcg · Most common: 2000+ mcg

0–25
32
25–50
0
50–100
0
100–200
0
200–400
5
400–600
4
600–1000
9
1000–2000
33
2000+
39

How repeat users are trending

Among repeat reporters, 78% said they felt similar to their last entry, 22% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 94 days · Based on 23 repeat reporters

Research

Cited research (3)

Help

Frequently asked

What do PeptIQ users report about Semaglutide?

This page summarizes 26 anonymized self-reports from PeptIQ users who track Semaglutide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Semaglutide?

3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Semaglutide safe to use?

This wiki does not assess safety or recommend use. Semaglutide is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Semaglutide?

Research, primarily in animal models, suggests Semaglutide may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Semaglutide?

Semaglutide is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Semaglutide as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Semaglutide?

The safety and effectiveness of Semaglutide have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Semaglutide?

While there are over 200 published studies on Semaglutide, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source